<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34764380</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics.</ArticleTitle><Pagination><StartPage>22128</StartPage><MedlinePgn>22128</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22128</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-01499-6</ELocationID><Abstract><AbstractText>Delayed diagnosis and misdiagnosis are frequent in people with amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). Neurofilament light chain (NFL) and phosphorylated neurofilament heavy chain (pNFH) are elevated in ALS patients. We retrospectively quantified cerebrospinal fluid (CSF) NFL, CSF pNFH and plasma NFL in stored samples that were collected at the diagnostic work-up of ALS patients (n&#x2009;=&#x2009;234), ALS mimics (n&#x2009;=&#x2009;44) and controls (n&#x2009;=&#x2009;9). We assessed the diagnostic performance, prognostication value and relationship to the site of onset and genotype. CSF NFL, CSF pNFH and plasma NFL levels were significantly increased in ALS patients compared to patients with neuropathies &amp; myelopathies, patients with myopathies and controls. Furthermore, CSF pNFH and plasma NFL levels were significantly higher in ALS patients than in patients with other MNDs. Bulbar onset ALS patients had significantly higher plasma NFL levels than spinal onset ALS patients. ALS patients with C9orf72HRE&#xa0;mutations had significantly higher plasma NFL levels than patients with&#xa0;SOD1&#xa0;mutations. Survival was negatively correlated with all three biomarkers. Receiver operating characteristics showed the highest area under the curve for CSF pNFH for differentiating ALS from ALS mimics and for plasma NFL for estimating ALS short and long survival. All&#xa0;three biomarkers have diagnostic value in differentiating ALS from clinically relevant ALS mimics. Plasma NFL levels can be used to differentiate between clinical and genetic ALS subgroups.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Behzadi</LastName><ForeName>Arvin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9347-0364</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, 901 85, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pujol-Calder&#xf3;n</LastName><ForeName>Fani</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7920-2884</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjust</LastName><ForeName>Anton E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0003-2369-4319</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, 901 85, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuolikainen</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0838-5526</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;glund</LastName><ForeName>Kina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1213-9953</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2911-6026</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, 901 85, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2708-7372</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter Munch</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, 901 85, Ume&#xe5;, Sweden. Peter.Andersen@umu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LVNFOU939000</GrantID><Agency>Region V&#xe4;sternorrland</Agency><Country/></Grant><Grant><GrantID>633413</GrantID><Agency>Horizon 2020</Agency><Country/></Grant><Grant><GrantID>860197</GrantID><Agency>Horizon 2020</Agency><Country/></Grant><Grant><GrantID>2012-0262</GrantID><Agency>Hj&#xe4;rnfonden</Agency><Country/></Grant><Grant><GrantID>2012-0305</GrantID><Agency>Hj&#xe4;rnfonden</Agency><Country/></Grant><Grant><GrantID>2013-0279</GrantID><Agency>Hj&#xe4;rnfonden</Agency><Country/></Grant><Grant><GrantID>2016-0303</GrantID><Agency>Hj&#xe4;rnfonden</Agency><Country/></Grant><Grant><GrantID>2020-0353</GrantID><Agency>Hj&#xe4;rnfonden</Agency><Country/></Grant><Grant><GrantID>RDAPB-201809-2016615</GrantID><Agency>Alzheimer's Drug Discovery Foundation</Agency><Country/></Grant><Grant><GrantID>JPND2019-466-236</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research</Agency><Country/></Grant><Grant><GrantID>AF-742881</GrantID><Agency>Swedish Alzheimer Foundation</Agency><Country/></Grant><Grant><GrantID>2012.0091</GrantID><Agency>Knut och Alice Wallenbergs Stiftelse</Agency><Country/></Grant><Grant><GrantID>2014.0305</GrantID><Agency>Knut och Alice Wallenbergs Stiftelse</Agency><Country/></Grant><Grant><GrantID>2020.0232</GrantID><Agency>Knut och Alice Wallenbergs Stiftelse</Agency><Country/></Grant><Grant><GrantID>2012-0262</GrantID><Agency>Vetenskapsr&#xe5;det</Agency><Country/></Grant><Grant><GrantID>2012-0305</GrantID><Agency>Vetenskapsr&#xe5;det</Agency><Country/></Grant><Grant><GrantID>2013-0279</GrantID><Agency>Vetenskapsr&#xe5;det</Agency><Country/></Grant><Grant><GrantID>2016-0303</GrantID><Agency>Vetenskapsr&#xe5;det</Agency><Country/></Grant><Grant><GrantID>2020-0353</GrantID><Agency>Vetenskapsr&#xe5;det</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.B. declares no disclosures relevant to the manuscript. F.P.C. declares no disclosures relevant to the manuscript. A.E.T. declares no disclosures relevant to the manuscript. A.W. declares no disclosures relevant to the manuscript. K.H. declares no disclosures relevant to the manuscript. K.F. declares no disclosures relevant to the manuscript. E.P. declares no disclosures relevant to the manuscript. K.B. served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H.Z. reports that he has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. P.M.A. reports grants from the Swedish Research Council, the Swedish Brain Foundation, the Knut and Alice Wallenberg Foundation, the Ulla-Carin Lindquist Foundation; has been/is a consultant for Biogen, Orphazyme A/S, Hoffman la Roche/Genentech and Regeneron on matters regarding ALS genetics and clinical trials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34764380</ArticleId><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-01499-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-01499-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Belsh JM. Diagnostic challenges in ALS. Neurology. 1999;53:S26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yedavalli VS, Patil A, Shah P. Amyotrophic lateral sclerosis and its mimics/variants: A comprehensive review. J. Clin. Imaging Sci. 2018;8:53&#x2013;53. doi: 10.4103/jcis.JCIS_40_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jcis.JCIS_40_18</ArticleId><ArticleId IdType="pmc">PMC6302559</ArticleId><ArticleId IdType="pubmed">30652056</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J. Neurol. 2009;256:615&#x2013;619. doi: 10.1007/s00415-009-0131-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-0131-z</ArticleId><ArticleId IdType="pubmed">19296046</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch. Neurol. 2000;57:109&#x2013;113. doi: 10.1001/archneur.57.1.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.1.109</ArticleId><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population validation of a scoring system and a model for survival prediction. Brain. 1995;118:707&#x2013;719. doi: 10.1093/brain/118.3.707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.3.707</ArticleId><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, et al. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120(Pt 10):1723&#x2013;1737. doi: 10.1093/brain/120.10.1723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.10.1723</ArticleId><ArticleId IdType="pubmed">9365366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange DJ, et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann. Neurol. 2017;81:837&#x2013;848. doi: 10.1002/ana.24950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24950</ArticleId><ArticleId IdType="pmc">PMC5518287</ArticleId><ArticleId IdType="pubmed">28480639</ArticleId></ArticleIdList></Reference><Reference><Citation>Birve A, et al. A novel SOD1 splice site mutation associated with familial ALS revealed by SOD activity analysis. Hum. Mol. Genet. 2010;19:4201&#x2013;4206. doi: 10.1093/hmg/ddq338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq338</ArticleId><ArticleId IdType="pubmed">20709807</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart HG, et al. Clinicopathological phenotype of ALS with a novel G72C SOD1 gene mutation mimicking a myopathy. Muscle Nerve. 2006;33:701&#x2013;706. doi: 10.1002/mus.20495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20495</ArticleId><ArticleId IdType="pubmed">16435343</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Moens TG, Isaacs AM. Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies. EMBO Mol. Med. 2017;9:853&#x2013;855. doi: 10.15252/emmm.201707848.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707848</ArticleId><ArticleId IdType="pmc">PMC5524429</ArticleId><ArticleId IdType="pubmed">28533210</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science. 1998;279:514&#x2013;519. doi: 10.1126/science.279.5350.514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.279.5350.514</ArticleId><ArticleId IdType="pubmed">9438837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Liem RK. Alpha-internexin and peripherin: Expression, assembly, functions, and roles in disease. Methods Enzymol. 2016;568:477&#x2013;507. doi: 10.1016/bs.mie.2015.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mie.2015.09.012</ArticleId><ArticleId IdType="pubmed">26795481</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1 genotype. Eur. J. Neurol. 2007;14:1329&#x2013;1333. doi: 10.1111/j.1468-1331.2007.01972.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01972.x</ArticleId><ArticleId IdType="pubmed">17903209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: A possible marker of disease severity and progression. Eur. J. Neurol. 2012;19:1561&#x2013;1567. doi: 10.1111/j.1468-1331.2012.03777.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03777.x</ArticleId><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE. 2013;8:e75091. doi: 10.1371/journal.pone.0075091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075091</ArticleId><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J. Neurochem. 2011;117:528&#x2013;537. doi: 10.1111/j.1471-4159.2011.07224.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07224.x</ArticleId><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl PP, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2016;17:404&#x2013;413. doi: 10.3109/21678421.2016.1167913.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1167913</ArticleId><ArticleId IdType="pubmed">27415180</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852&#x2013;856. doi: 10.1212/01.wnl.0000203120.85850.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/wnl.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, et al. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J. Neurol. Sci. 2015;353:122&#x2013;129. doi: 10.1016/j.jns.2015.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.032</ArticleId><ArticleId IdType="pubmed">25958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur. J. Neurol. 2012;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, et al. EFNS task force on management of amyotrophic lateral sclerosis: Guidelines for diagnosing and clinical care of patients and relatives. Eur. J. Neurol. 2005;12:921&#x2013;938. doi: 10.1111/j.1468-1331.2005.01351.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2005.01351.x</ArticleId><ArticleId IdType="pubmed">16324086</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Synofzik M, et al. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Hum. Mol. Genet. 2012;21:3568&#x2013;3574. doi: 10.1093/hmg/dds188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds188</ArticleId><ArticleId IdType="pubmed">22595972</ArticleId></ArticleIdList></Reference><Reference><Citation>Akimoto C, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J. Med. Genet. 2014;51:419&#x2013;424. doi: 10.1136/jmedgenet-2014-102360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2014-102360</ArticleId><ArticleId IdType="pmc">PMC4033024</ArticleId><ArticleId IdType="pubmed">24706941</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: Analytical validation and clinical evaluation. Alzheimers Res. Ther. 2018;10:8. doi: 10.1186/s13195-018-0339-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0339-1</ArticleId><ArticleId IdType="pmc">PMC6389166</ArticleId><ArticleId IdType="pubmed">29370869</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujol-Calder&#xf3;n F, et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neurosci. Lett. 2019;698:58&#x2013;63. doi: 10.1016/j.neulet.2018.12.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.12.042</ArticleId><ArticleId IdType="pubmed">30599262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 2016;54:1655&#x2013;1661. doi: 10.1515/cclm-2015-1195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2015-1195</ArticleId><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari Bidhendi E, et al. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. Acta Neuropathol. 2018;136:939&#x2013;953. doi: 10.1007/s00401-018-1915-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1915-y</ArticleId><ArticleId IdType="pmc">PMC6280858</ArticleId><ArticleId IdType="pubmed">30284034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2019;45:291&#x2013;304. doi: 10.1111/nan.12511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, et al. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 2018;265:510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:467&#x2013;472. doi: 10.1136/jnnp-2012-303768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong ZY, et al. Neurofilament subunit L levels in the cerebrospinal fluid and serum of patients with amyotrophic lateral sclerosis. Neurodegener. Dis. 2018;18:165&#x2013;172. doi: 10.1159/000488681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000488681</ArticleId><ArticleId IdType="pubmed">29898446</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, et al. Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:12. doi: 10.1136/jnnp-2015-311387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis, L., Oudart, H., Rene, F., Gonzalez de Aguilar, J. L. &amp; Loeffler, J. P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. U S A101, 11159&#x2013;11164. 10.1073/pnas.0402026101 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, et al. Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort. J. Neurol. Neurosurg. Psychiatry. 2019;90:666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse van Mantgem MR, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: A population-based study. J. Neurol. Neurosurg. Psychiatry. 2020;91:867&#x2013;875. doi: 10.1136/jnnp-2020-322909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322909</ArticleId><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J. Rare. Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, et al. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J. Neurol. 2020;267:2272&#x2013;2280. doi: 10.1007/s00415-020-09838-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09838-9</ArticleId><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="pubmed">32306171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia MC, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: Examination of symptoms and signs at disease onset and during follow-up. Arch. Neurol. 2007;64:232&#x2013;236. doi: 10.1001/archneur.64.2.232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.2.232</ArticleId><ArticleId IdType="pubmed">17296839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WK, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009;73:1686&#x2013;1692. doi: 10.1212/WNL.0b013e3181c1dea3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1dea3</ArticleId><ArticleId IdType="pmc">PMC2788803</ArticleId><ArticleId IdType="pubmed">19917992</ArticleId></ArticleIdList></Reference><Reference><Citation>Koel-Simmelink MJA, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J. Immunol. Methods. 2014;402:43&#x2013;49. doi: 10.1016/j.jim.2013.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2013.11.008</ArticleId><ArticleId IdType="pubmed">24275679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant HC. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem. J. 1988;256:665&#x2013;668. doi: 10.1042/bj2560665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2560665</ArticleId><ArticleId IdType="pmc">PMC1135461</ArticleId><ArticleId IdType="pubmed">2851997</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MV, Yuan A, Campbell J, Kumar A, Nixon RA. The C-terminal domains of NF-H and NF-M subunits maintain axonal neurofilament content by blocking turnover of the stationary neurofilament network. PLoS ONE. 2012;7:e44320&#x2013;e44320. doi: 10.1371/journal.pone.0044320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044320</ArticleId><ArticleId IdType="pmc">PMC3448626</ArticleId><ArticleId IdType="pubmed">23028520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996;67:2013&#x2013;2018. doi: 10.1046/j.1471-4159.1996.67052013.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67052013.x</ArticleId><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann. Clin. Transl. Neurol. 2015;2:748&#x2013;755. doi: 10.1002/acn3.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 2016;79:152&#x2013;158. doi: 10.1002/ana.24552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302&#x2013;2309. doi: 10.1212/wnl.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>